Early Intervention with Epinephrine is Critical in a Type I Severe Allergic Reaction
We estimate approximately 25 to 40 million people in the United States have experienced severe Type 1 allergic reactions that may lead to anaphylaxis, but only about 3.3 million of them filled a prescription in 2021 for an epinephrine intra-muscular injectable device, including auto-injectors.
Of those 3.3 million people, roughly half don't carry these devices due to many drawbacks that can result in patient and caregiver injury, hesitation and delays in administration principally because of apprehension and pain of needles. In turn, the failure or delay of epinephrine delivery can allow the allergic reaction to progress in severity causing life-threatening symptoms or events that potentially require emergency services and/or hospitalization.
Early Intervention with Epinephrine is Critical in a Type I Severe Allergic Reaction
We estimate approximately 25 to 40 million people in the United States have experienced severe Type 1 allergic reactions that may lead to anaphylaxis, but only about 3.3 million of them filled a prescription in 2021 for an epinephrine intra-muscular injectable device, including auto-injectors.
Of those 3.3 million people, roughly half don't carry these devices due to many drawbacks that can result in patient and caregiver injury, hesitation and delays in administration principally because of apprehension and pain of needles. In turn, the failure or delay of epinephrine delivery can allow the allergic reaction to progress in severity causing life-threatening symptoms or events that potentially require emergency services and/or hospitalization.
Epinephrine Nasal Spray
All systemic allergic reactions have the potential of progressing to anaphylaxis and becoming life-threatening. Epinephrine needs to be given as soon as symptoms occur because it is the only medication proven to stop a potentially life-threatening allergic reaction. Delay or failure to use epinephrine greatly increases the chance of hospitalization and has been associated with fatalities.
ARS is developing a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis. Intended for use at the first signs of an allergic response, a needle-free nasal spray may allow for improved patient and caregiver preparedness and response, to give epinephrine quickly, confidently, and without hesitation that is caused by fear of needles.
It is our commitment to provide patients and their families with a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis.
Epinephrine Nasal Spray
All systemic allergic reactions have the potential of progressing to anaphylaxis and becoming life-threatening. Epinephrine needs to be given as soon as symptoms occur because it is the only medication proven to stop a potentially life-threatening allergic reaction. Delay or failure to use epinephrine greatly increases the chance of hospitalization and has been associated with fatalities.
ARS is developing a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis. Intended for use at the first signs of an allergic response, a needle-free nasal spray may allow for improved patient and caregiver preparedness and response, to give epinephrine quickly, confidently, and without hesitation that is caused by fear of needles.
It is our commitment to provide patients and their families with a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis.
Device Characteristics
Needle-Free Administration
Proven Device Used by Current Emergency Therapies
Pocket-Sized Device
No Risk of Needle-Related Injuries
ARS recognizes that there are multiple pitfalls in treatments for severe allergic reaction, which include:
Fear of needles and anxiety about injecting oneself or a loved one
Needle-related injuries (e.g. lacerations, blood vessel injections)
Device bulkiness and portability
Miscomprehension and complexity of proper administration
Misconception of when to use, resulting in hesitation
*Data on file
- Warren et al. Epinephrine auto-injector carriage and use practices among US children, adolescents and adults. Ann Allergy Asthma Immunol. 2018; 121(4): 479 – 489e2
- Data on file from ARS market research studies.
- Brooks et al. Diagnosis and treatment of food allergic reactions in pediatric emergency settings. Ann Allergy Asthma Immunol. 2017; 119(5): 467-468
- El Turki et al. A systematic review of patients’, parents’ and healthcare professionals’ adrenaline auto-injector administration techniques. Emergency Medical Journal. 2017; 34(6): 403-416
- Asthma and Allergy Foundation of America. My Life with Food Allergy Patient Survey Report 2019